CROI 2019 Program and Conference Information

Oral Sessions

155 4:30

MECHANISMS UNDERLYING LOSS OF ILCs INHIV/ SIV-INFECTED INDIVIDUALS Jason Brenchley, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA MEMORY NK CELLS AS NOVEL EFFECTORS AGAINST HIV AND SIV R. Keith Reeves, Harvard Medical School, Boston, MA, USA HIV SUPPRESSION BY CD8+LYMPHOCYTES Deanna Kulpa, Emory University, Atlanta, GA, USA

156 5:00

157 5:30

Symposium S-8 TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT Room 6AB Target Audience: This session is directed to clinicians and scientists who are interested in understanding current challenges and questions regarding antiretroviral treatment for people living with HIV. Level of Knowledge: It is assumed that the participants have an understanding of the principles of antiretroviral therapy and the antiretroviral agents that are commonly used to treat HIV infection. Objectives: At the completion of the session, participants will be able to: • Describe the trends in obesity and ART and impact on inflammation • Describe HIV neurocognitive decline, the aging brain, and neurodegenerative disease 4:00 PM - 6:00 PM CME

• Enumerate HIV diagnostic dilemmas in the setting of PrEP • Describe 2-drug ART for initial therapy and maintenance Conveners Jennifer Hoy, Alfred Hospital and Monash University, Melbourne, Victoria, Australia Georg Behrens, Medizinische Hochschule Hannover, Hannover, Germany 158 OBESITY: A GROWING PROBLEM IN ANTIRETROVIRAL THERAPY John R. Koethe, Vanderbilt University, Nashville, TN, USA I KEEP FORGETTING: HIV, AGING, AND COGNITIVE DISORDERS Victor Valcour, University of California San Francisco, San Francisco, CA, USA 4:00 4:30 159

160 5:00

PrEP FAILURES: DIAGNOSIS, RESISTANCE, AND TREATMENT Jean-Michel Molina, Hôpital Saint-Louis, Paris, France CAN TWO DRUGS TANGO: THE ROLE OF DUAL THERAPY Laura Waters, Mortimer Market Centre, London, UK

161 5:30

Oral Sessions • Thursday

CROI 2019 60